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CObjectives: This study assessed the cost-effectiveness of sertindole
compared with existing atypical antipsychotics in the treatment of pa-
tients with schizophrenia in the South Korean setting. Methods: A
arkov model was developed to estimate the cost-effectiveness of
ertindole compared with risperidone, olanzapine, and quetiapine
ith a cycle of 6 months on a 5-year time horizon. Effectiveness was
efined as the length of timewithout relapse and quality-adjusted life-
ears. Parameter estimates including drug-induced adverse events,
ompliance rate, and relapse rate were based on published literature
nd clinical trial data. Resource utilization datawere obtained from the
010 National Health Insurance reimbursement data, and costs were
stimated from the health care system’s perspective. A discount rate of
% was applied to both cost and effectiveness. One-way sensitivity
nalyses andprobabilistic sensitivity analysiswere carried out to check
he robustness of the base-case analysis. Results: The length of time O
e no
licy a
al So
doi:10.1016/j.vhri.2012.03.015ithout relapse was 1.90 years for all study drugs. The estimated qual-
ty-adjusted life-years were 1.27 for sertindole, followed by quetiapine,
isperidone, and olanzapine. Total costswere 10.51millionKoreanwon
KRW) for sertindole, 12.86 million KRW for olanzapine, 8.38 million
RW for risperidone, and 8.91 million KRW for quetiapine. The incre-
ental cost-effectiveness ratios showed that sertindole was dominant
nly over olanzapine andwas not cost-effective comparedwith risperi-
one and quetiapine. Various sensitivity analyses confirmed the re-
ults from the base-case analysis. Conclusions: Sertindole may be
onsidered a valuable treatment option for South Korean patients who
ave failed the therapy with other atypical antipsychotic agents.
eywords: antipsychotics, atypical, cost-effectiveness, schizophrenia,
ertindole.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Schizophrenia is a mental illness with substantial short-term and
long-term consequences for individuals, their families, the health
care system, and society. Schizophrenia is a relatively common
illness and the most common form of psychotic disorder. The 12-
month prevalence of schizophrenia reported in a South Korean
epidemiological study was 0.3% in 2006 [1]. The economic burden
of schizophrenia is high [2]. According to National Health Insur-
ance (NHI) claims data in South Korea (hereafter, Korea), the ex-
penditure on schizophrenia accounted for 0.7% of total health in-
surance expenditures in 2008 [3]. In schizophrenia, early onset,
persistent psychotic symptoms even with antipsychotic treat-
ment, adverse events, frequent failure of treatments, and pro-
longed functional impairment all contribute to making schizo-
phrenia a particularly costly illness [4].
In the late 1990s, progress was made in the management of
schizophrenia following the introduction of atypical antipsychotic
medications that demonstrated marked improvements in tolera-
bility profiles when compared with typical antipsychotic medica-
tions. But current pharmacological options still carry some limita-
tions. Atypical antipsychotic medications are associated with
various adverse events such as extrapyramidal symptoms (EPS),
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Published by Elsevier Inc.weight gain,metabolic disorders including diabetesmellitus, som-
nolence, and sexual dysfunction. The tolerability profiles differ
between atypical antipsychotic medications, and drug-induced
side effects have been suggested to be one of the main factors
contributing to treatment nonadherence [5].
Sertindole (Serdolect) is an antipsychotic drug with affinity for
dopamine D2, serotonin 5-HT2A and 5-HT2C, and alpha1-adreno-
receptors. In Europe, sertindole was approved and marketed in 19
countries from 1996. In the United States, it first applied for Food
and Drug Administration (FDA) approval. But this application was
withdrawn in 1998 following concerns over adverse events, that is,
the increased risk of sudden death from QT prolongation [6]. In
1999, however, it was revealed that the adverse event was not
associated with increasing rates of cardiac arrhythmias and that
patients on sertindole had the same overallmortality rate as those
on risperidone using the results of the Sertindole Cohort Prospec-
tive study [7]. As of January 2012, the drug has not been approved
by the FDA for use in the United States [8].
Despite concerns about safety issues, sertindole has a good
tolerability profile, which is likely to favor long-term treatment
adherence, reduce relapse, rehospitalization, and suicide, and im-
prove overall functioning. Sertindole is prescribed to patients who
are intolerant to at least one other antipsychotic agent. All pa-
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be increased by increments of 4 mg after 4 to 5 days on each dose
until the optimal daily maintenance dose, usually within the
range of 12 to 20 mg, is reached [7]. Electrocardiogram (ECG) mon-
toring is required before and during treatment.
Two head-to-head comparisons of sertindole and risperidone
howed equivalent efficacy on positive symptoms such as delu-
ion, hallucination, hyperactivity, conceptual disorganization,
nd so onmeasured by the Positive and Negative Syndrome Scale.
or negative symptoms such as emotional withdrawal, difficulty
n abstract thinking, and poor rapport, one study obtained equiv-
lent effects [9], while the other study obtained superior effects of
ertindole to risperidone [10]. Sertindole should not be used as a
rst-line treatment for first-episode patients with schizophrenia
ecause of QT prolongation. However, it has a side-effect profile
hatmakes it a favorable alternative formany patients who do not
espond well to the initial choice of antipsychotic drugs [11].
According to IMS health data in 2009, the market size of antip-
sychotics was almost 140 billion Korean won (KRW) in Korea.
Among the antipsychotics, risperidone accounted for 26.24% of
the market share, olanzapine 25.53%, and quetiapine 14.45%.
Sertindole is not launched yet in Korea because of delayed ap-
proval of US FDA. But once it is approved by the Korean FDA, it is
expected to compete with the other antipsychotic drugs in this
market.
Using a decision analysis model, therefore, this study aimed to
examine the cost-effectiveness of sertindole compared with ris-
peridone, olanzapine, and quetiapine in the treatment of schizo-
phrenia in the Korean health care setting.
Methods
Study design
This study is a cost-effectiveness analysis of atypical antipsy-
chotic drugs for the management of schizophrenia. Sertindole
was compared with three atypical antipsychotic medications
that had the highest average market share for 5 years in Korea
according to IMS health data: risperidone, olanzapine, and que-
tiapine [12] (Table 2).
Markov model for cost-effectiveness analysis is particularly
suitable for the evaluation of chronic diseases such as schizophre-
nia. The study population consisted of treatment-resistant pa-
tients with schizophrenia requiring hospitalization. It was as-
sumed that patients entered into the model on experiencing
intolerance to their antipsychotic treatment during an episode of
acute psychopathology after already having received a previous
antipsychotic treatment.
After starting treatment on the recommended daily dose of a
given drug, patients can either die or remain alive at the first
chance node of the decision tree. Patients then enter either of
Fig. 1 – Markov model for cost-effectiveness analysis. Comp
symptoms; M, Markov; Rel +, relapse; Rel −, nonrelapse.two possible paths: drop out or remain on treatment. Dropoutpatients are assumed to disrupt the antipsychotic treatment for
a cycle of 6 months, after which they can either return to treat-
ment because of relapse or remain as dropouts. Patients who
remain on treatment are then at risk of experiencing different
adverse events: EPS, weight gain (and associated diabetes), sex-
ual dysfunction, somnolence, and other adverse events. The
degree to which patients comply is assumed to be the same
across medication regimens administered but to differ accord-
ing to the side effects experienced. The patients may therefore
be compliant or noncompliant. At the end of the 6-month period
covered by the model, patients can be in one of two health
states: relapse and nonrelapse. The risk of relapse increases
with decreasing compliance to treatment. The patients with
relapse are assumed to receive inpatient care in hospitals while
the patients with no relapse are assumed to continue outpatient
care (Fig. 1).
The length of a cycle was 6 months, which was based on clin-
ical practice patterns and expert opinion. The decision to use a
6-month cycle was clinically justified, because it is currently ac-
cepted that any deterioration in schizophrenia that occurs within
6months following a relapse should be considered as being part of
that relapse [13]. As is commonly required in pharmacoeconomic
analyses, a 5-year time horizon was employed [14] and a discount
rate of 5% was applied to both cost and effectiveness.
Data
Clinical inputs
Clinical inputs of the treatment are based on the results of random
double-blind comparative clinical trials.Weperformed systematic
reviews by searching electronic databases: PubMed, EMBASE, Co-
chrane Library (Central register of controlled trial; CENTRAL),
MEDLINE (OVID), Korea medicine database (KMBASE), and RISS
database (produced by Korea Education and Research Information
Service) from 1990 to March 2011. The keywords were “schizo*,”
“relapse,” “hospitalization,” “sertindole,” “risperidone,” “olanzap-
ine,” and “quetiapine” (Fig. 2). The inclusion criteria were to only
accept schizophrenia or schizoaffective patients, flexible dose,
and head-to-head trials between comparator and risperidone as
common reference. Consequently, we selected seven randomized
controlled clinical trials [10,15–20] (Table 1).
Drug-specific input data on adverse events for each drug
were obtained through indirect comparison. Using meta-analy-
sis, relative risks between drugs were derived on the basis of
percentage of patients experiencing adverse events from se-
lected articles (Table 2).
Non–drug-specific input data used in this study were based on
published articles (Table 2). These included premature dropout
rate, compliance rates, relapse rates by compliance, andmortality
rate. Dropout rates were derived from data on flexible doses for
patients with schizophrenia [21]. Compliance rates depended on
mpliant; Comp −, noncompliant; EPS, extrapyramidal+, codifferent adverse events (EPS, weight gain, somnolence, and sex-
a
r
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is clearly associated with an increased risk of schizophrenic re-
lapse [22]. Relapse rates were independent of the antipsychotic
Fig. 2 – Flow of systematic review. RCT, randomized
controlled trial.
Table 1 – Summary of included studies.
Source Country Diagnosis
Conley and Mahmoud [19] United States Schizophrenia or
schizoaffective
disorder
(DSM-IV)
Gureje et al. [20] Australia,
New
Zealand
Schizophrenia,
schizoaffective
disorder, or
schizophreniform
disorder
(DSM-IV)
Lieberman et al. [15] United States Schizophrenia (DSM-IV)
Alvarez et al. [16] Spain Schizophrenia (DSM-IV)
Azorin et al. [10] France Schizophrenia (DSM-IV)
Potkin et al. [17] United States Schizophrenia or
schizoaffective
disorder (DSM-IV)
Zhong et al. [18] United States Schizophrenia (DSM-IV)DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edmedication taken, but indirectly dependent on the adverse events
experienced because they impact compliance rates. Different re-
lapse rates were applied depending on compliance [15]. The mor-
tality rate of schizophrenia was estimated by using the prevalence
rate of schizophrenia from Korea national statistical database [24]
nd the mortality rates of the whole mental disorder from a Ko-
ean epidemiological study [1].
Economic input
Costs were estimated from the health care system’s perspective.
Indirect costs such as productivity loss were not included because
of limited availability of Korean data. Direct costs consist of health
care costs and non–health care costs. Commonly, health care
costs include the costs for physician visits, medication, hospital-
ization, laboratory tests, mental therapy, mental health day-care
center, and adverse events. Health care costs were estimated by
gross costing by using 2010 Health Insurance Review and Assess-
ment Service (HIRA) data in Korea [3]. HIRA data are a claims data
of NHI that include frequency of patient visit and total cost of
health care utilization by disease classification. Annual costs of
in-/outpatient care for schizophrenia were obtained from HIRA
data and were divided by 2 to get 6-month costs for model input.
The same costs of adverse events were applied for each compar-
ator in themodel, except for ECGmonitoring cost added on sertin-
dole. It was assumed that there was no difference in health care
resource utilization among adverse events (EPS, weight gain, som-
nolence, and sexual dysfunction) except formedication costs. The
drug costs of benzotropine for EPS, metformin for diabetes, and
modafinil for somnolence were included while weight gain and
sexual dysfunction were assumed to have no prescription. The
drug costs included in themodel were obtained from theweighted
average annual drug price in HIRA [25] (Table 3). Prices were pre-
sented according to the mean daily dose for each drug by inpa-
tients/outpatients. The mean daily doses for sertindole and com-
parators were based on a previous study in Korea [27]. All the
health care costs were adjusted for inflation in 2010 by health care
inflation rate of national statistics [28].
Non–health care costs included time and travel costs of the
patients in the treatment of schizophrenia. Estimation of time
and travel costs was based on the data from 2005 Korea National
Treatment Comparison F/U
period
Drugs Dose
(mg/d)
n Drugs Dose
(mg/d)
n
nzapine 5–20 189 Risperidone 2–6 188 8 wk
nzapine 10–20 32 Risperidone 4–8 33 30 wk
nzapine 7.5–30 336 Risperidone 1.5–6.0 341 18 mo
etiapine 200–800 337
nzapine 10 120 Risperidone 3 115 12 mo
tindole 12–24 98 Risperidone 4–10 89 12 wk
etiapine 400–600 156 Risperidone 4–6 153 42 d
etiapine 200–800 338 Risperidone 2–8 335 8 wkOla
Ola
Ola
Qu
Ola
Ser
Qu
Quition; F/U, follow up.
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were estimated by multiplying the average number of visits to hos-
pital or clinic obtained from NHANES by average wage and employ-
ment rate in 2010 [28]. The transportation costs of outpatients and
inpatients obtained fromNHANESwere adjusted for inflation during
the period between 2005 and 2010 by 11.8%.
Utility
To get quality-adjusted life-years (QALYs), utility values for each
state experienced in the treatment pathways were employed. The
utility weights were obtained from the published data of health-
related quality of life of illness from the Korean population, which
was measured by using EuroQol five-dimensional questionnaire
validated in Korean language [23]. The utility weight was multi-
plied by the time spent in that state for each branch of the model
and summed across all branches to get QALYs.
Analysis
The main outcome measure was time without relapse (TwR). In
addition, QALYs were calculated on the basis of utility values of
each health state in the model. The costs of treatment were
assessed on the basis of typical resource use in Korea associated
with each different treatment path. The cost per outcome, that
is, either TwR or QALY, was expressed by using incremental
cost-effectiveness ratio of sertindole versus comparators.
To check uncertainties for economic modeling for schizophre-
nia, we conducted one-way sensitivity analysis and probability
sensitivity analysis (PSA). The sensitivity analyses were carried
out on parameters such as compliance rate, relapse rate, drug cost
of sertindole, and discount rate. PSA was conducted on the as-
Table 2 – Model input: Effectiveness data.
Sales market share of atypical antipsychotics in Korea1
Risperidone
Olanzapine
Quetiapine
Drug-specific input2
Adverse event RR-EPS
Sertindol vs. risperidone
Olanzapine vs. risperidone
Quetiapine vs. risperidone
Adverse event RR-Weight gain
Sertindol vs. risperidone
Olanzapine vs. risperidone
Quetiapine vs. risperidone
Adverse event RR-Somnolence
Sertindol vs. risperidone
Olanzapine vs. risperidone
Quetiapine vs. risperidone
Adverse event RR-Sexual dysfunction
Sertindol vs. risperidone
Olanzapine vs. risperidone
Quetiapine vs. risperidone
HRQOL6
Healthy: 0.88 (0.20), illness: 0.73 (0.31)
Mortality rate of schizophrenia7 2.82 per 10,000 person
Sources. 1IMS Health Data [12]; 2Azorin et al. [10] andmeta analysis; 3M
and 7Korea Statistical Information Service [24].
EPS, extrapyramidal symptoms; HRQOL, health-related quality of life
* Conditional probability p(x | y): Probability of x given that y.
† P(relapse|comp) means the probability of relapse() occurring u
of no relapse() occurring under noncompliant patient().sumption of the beta distribution for effectiveness parameters andthe normal distribution for all the costs according to the guideline
of pharmacoeconomic evaluation in HIRA [29].
All analyses were performed by using Tree-Age Pro 2009 (Tree-
Age Software, Williamstown, MA).
Results
Based on the model, sertindole showed nearly equivalent out-
comes comparedwith its comparators. The length of TwRwas 1.90
years for all study drugs during 5 years on model projection. The
estimated QALYs were 1.27 for sertindole, followed by quetiapine,
risperidone, and olanzapine. Total costs including in- and outpa-
tient care were 10.51 million KRW for sertindole, 12.86 million
KRW for olanzapine, 8.38 million KRW for risperidone, and 8.91
million KRW for quetiapine. The incremental cost-effectiveness
ratios showed that sertindole was dominant only over olanzapine
andwas not cost-effective compared with risperidone and quetia-
pine (Table 4).
Various one-way sensitivity analyses showed that sertindole
was still a dominant alternative to olanzapine while it had very
high incremental cost-effectiveness ratios compared with risperi-
done and quetiapine. The compliance rate connected to EPS had to
be increased to 50% to make sertindole a cost-neutral alternative
to comparators. The main driver in the difference in total costs
between sertindole and comparators was inpatient care. When
the resource utilization of inpatient care was reduced by 50%,
sertindole was still the dominant treatment strategy compared
with olanzapine. Changes in the time frame of the analysis from 5
years to 3 years and 10 years did not affect the results from the
base-case analysis. Neither did the changes in the discount rate
Value
26.24%
25.53%
14.45%
alue Non–drug-specific input Value
Dropout rate3
0.13-1.28) EPS 3.97%
0.51-0.91) Weight gain 3.97%
0.42-0.77) Somnolence 1.78%
Sexual dysfunction 4.86%
0.71-2.44) Total 14.59%
1.57-2.98) Compliance rate4
0.81-1.44) EPS 96.03%
Weight gain 96.03%
0.40-2.77) Somnolence 98.22%
0.86-1.20) Sexual dysfunction 95.14%
1.05-1.49) Total 85.41%
Conditional probability5,*
.03-20.37) P(relapse|comp)† 0.12
0.99-1.71) P(relapse|comp) 0.42
0.99-1.71) P(relapse|comp) 0.89
P(relapse|comp) 0.58
et al. [21]; 4Hansen et al. [22]; 5Lieberman et al. [15]; 6Seong et al. [23];
relative risk.
compliant patient(), and P(relapse|comp) means the probabilityV
0.41 (
0.68 (
0.57 (
1.31 (
2.16 (
1.08 (
1.05 (
1.02 (
1.25 (
4.59 (1
1.30 (
1.30 (
artin
; RR,
nderfrom 5% to 3% and 7%. On the other hand, the results of PSA,
h Ins
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dole had nearly the equivalent effectiveness to its comparators
and that it was cheaper than only olanzapine among other atypi-
cal antipsychotic medications (Fig. 3).
Discussion
In schizophrenia, failure in therapy is particularly expensive
and is due to several factors such as lack of efficacy, side effects,
nonresponsiveness to treatment, and repetitive hospitaliza-
tions.
When compared with typical antipsychotic medication,
atypical antipsychotic medications have improved the treat-
ment of schizophrenia because they are associated with signif-
icantly fewer extrapyramidal side effects. This has, however,
renewed attention toward other side effects such as weight
gain, diabetes, sexual dysfunction, and somnolence. Because of
the individual patients’ response and tolerance of specific com-
pounds, many patients need to switch from one compound to
another. Consequently, important unmet needs exist for treat-
ments that can fulfill individual patients’ needs in terms of re-
sponse and tolerability.
Table 3 – Model input: Cost data.
Direct health care cost
Drug mean dose and cost per day1
Sertindole 1
Risperidone 4.
Olanzapine 10.8
Quetiapine 30
Outpatient visit cost2
Inpatient cost2
ECG examination2
Adverse event treatment cost1
EPS
Diabetes
Sedation
Direct non–health care cost3
Transportation cost
Outpatient per visit
Inpatient per visit
Time cost
Travel, waiting, and treatment for outpatient visit
Sources. 1) It was calculated byHIRA formula of pharmacoeconomic g
Health Insurance Corporation [3]; 3) Korea Center for Disease Contro
Note. Unit: Korean Won, .
ECG, electrocardiogram; EPS, extrapyramidal symptoms; HIRA, Healt
Table 4 – Results of base-case cost-effectiveness analysis.
Item Sertindole
Effectiveness
TwR (y) 1.90
QALY (y) 1.27
Costs (KRW) 10.51 M
Sertindole vs. comparator
ICER (TwR)
ICER (QALY)ICER, incremental cost-effectiveness ratio; KRW, Korean won; M, million;The purpose of this pharmacoeconomic analysis was to exam-
ine whether sertindole still fulfills the criteria for general reim-
bursement in the Korean NHI. The model was adapted to fit clini-
cal practice, current reimbursement criteria, and treatment costs
in Korea. Because of cardiovascular safety concerns, sertindole
should be used only for those patients who are intolerant to at
least one other antipsychotic agent.
By performing the cost-effectiveness analysis, it was possible
to compare the different atypical antipsychotic agents in the treat-
ment of patients with schizophrenia. The results showed that
sertindole was able to slightly increase the length of TwR and
QALY compared with other atypical antipsychotics for patients
with chronic schizophrenia. With regard to total treatment costs,
sertindole was cost-saving compared with olanzapine, but it was
involved in higher costs compared with risperidone and quetiap-
ine. In other words, sertindole was dominant over olanzapine
(greater effect at lower cost), but it was not a cost- effective alter-
native to risperidone and quetiapine.
This model was built on the hypothesis that the side effects
from antipsychotic therapy would influence the compliance rate
of the antipsychoticmedication in question. It is awell-known fact
that noncompliance to antipsychotic treatment is associated with
Value
Outpatient Inpatient
d 3,812 16 mg/d 3,812
d 1,640 5.25 mg/d 1,936
d 5,381 14.93 mg/d 7,715
d 1,925 400 mg/d 2,994
73,368/d
3,540,352/patient
19,040/y
980
72,074
53,228
8,830
22,544
80,064
ine [29] and 2010 annual HIRAweighted average price [25]; 2) National
urance Review and Assessment Service.
eridone Olanzapine Quetiapine
1.90 1.90 1.90
1.27 1.27 1.27
8.38 M 12.86 M 8.91 M
260 M Dominant 8000 M
710 M Dominant 1600 M6 mg/
1 mg/
5 mg/
0 mg/
uidel
l [26].Risp
4QALY, quality-adjusted life-year; TwR, time without relapse.
[[
[
[
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of antipsychotic drug treatment in terms of TwR was therefore
estimated in themodel on the basis of drug-specific data (percent-
ages of patients experiencing certain adverse events) derived from
clinical trial data. Only five adverse events (EPS, weight gain, dia-
betes, somnolence, and sexual dysfunction) were included be-
cause those were the major concomitant diseases and had great
effects on the compliance of schizophrenia patients.
Treatment with sertindole is associatedwith an increased risk of
QT prolongation. However, patients are closely monitored during
treatment and have their ECG taken every third month. QT prolon-
gation was not handled as a separate adverse event in the model,
only with the inclusion of the ECG costs in the sertindole branch.
Adverse events defined as “other adverse events” included all events
except EPS, weight gain, diabetes, somnolence, and sexual dysfunc-
tion. Because of the broad spectrum of other adverse events, they
were not associatedwith a cost in themodel. Because sertindole had
the lowest rate of “other” events among atypical antipsychotic
agents in themodel, the strategy of not including the costs for these
events was considered to be conservative.
There are some limitations in this study. One of the limitations
was the absence of direct comparative clinical trial data between
sertindole and its comparators, quetiapine and olanzapine, respec-
tively. This lack of direct comparison was resolved by employing
indirect comparisons of sertindole versus those two comparators
with risperidone as common reference. Another limitation was lack
of the detailed empirical data of resource utilization of Korean pa-
tients with schizophrenia. For example, such information as the
number of hospital/clinic visits of individual patients, the type and
amount of health services after relapse, and the type and cost of
treatment for adverse eventswasnot available because of protection
of personal information. Instead of themicrocosting method, there-
fore, this study used the gross-costing method based on aggregated
number of patients and hospital/clinic visits for 1 year and annual
total reimbursement cost in schizophrenia. Besides, indirect costs
were not considered because of the lack of data on productivity loss
of the patients with schizophrenia in Korea.
Despite the limitations mentioned above, this study has some
implications in a few aspects. First, in terms of decisions on the re-
imbursement in the KoreanNHI, the study results suggest the possi-
bility that sertindole could be used as another option of atypical
antipsychotic medication for the treatment of patients with schizo-
phreniawho do not respond to initialmedication. Second, it is antic-
ipated that, thoughnot yet launched, sertindolewill be able tohave a
room for themarket share and competition among atypical antipsy-
Fig. 3 – Cost-effectiveness (CE) scatter plot.chotic drugs in Korea if its price is set at an appropriate level. Third,because therehavenotbeenmanystudies conductedonschizophre-
nia in Korea, this study is meaningful in that it is a pharmacoeco-
nomic evaluation using the Markov model and the PSA.
Conclusions
Sertindole should not be used as first-line treatment for first-episode
patients with schizophrenia because of the QT prolongation. How-
ever, it has a side-effect profile that makes it a useful alternative for
many patients who do not respond well to the initial choice of anti-
psychotic drug. Sertindole demonstrated nearly equivalent out-
comes tootheratypical antipsychoticsandproved tobeacost-saving
alternative to olanzapine. Therefore, it is concluded that sertindole
may be considered as a treatment option for Korean patients who
have failed the therapy with other atypical antipsychotic agents.
Source of financial support: These findings are the result of work
supported by Lundbeck Korea Co. Ltd. The views expressed in this
article are those of the authors, and no official endorsement by Lun-
dbeck Korea Co. Ltd is intended or should be inferred.
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